Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, Egypt, shared a post on LinkedIn:
“By approaching the end of 2025, we decided to discuss the new results of clinical trials, which led to the approval of drugs and the change in international guidelines.
Yesterday, we interpreted those newly updated guidelines in real-world clinical practice.
I was so proud of the discussion made by young oncologists and pharmacists from different oncology centres all over Egypt with me while I was discussing data from clinical trials for advanced-stage endometrial cancer:
- RUBY
- NRG-GY018
- DUO-E
How can we look at overall survival data and progression-free survival data in relation to adverse events and financial toxicity?
How should we choose between
- Dostarlimab
- Pembrolizumab
- Durvalumab? as immunotherapy in combination with chemotherapy for endometrial cancer?
Should we add PARP inhibitors for all patients?
Discussion did never end, and patients are getting benefit of more discussion.
Thanks for Prof Nervana Hassan for discussion of ovarian cancer.”
More posts featuring Rasha Aboelhassan.